obesity drug news today glp-1 oct 27 2025 How Supply and Demand for Weight Loss Drugs is Playing Out in 2026 Use of diabetes and anti-obesity

I noticed immediate improvement with my one cat and slower improvement on my 2nd cat Both are doing well and have gained weight

Journal of exercise nutrition & biochemistry , 22 (4), 719

The human dopamine transporter (hDAT) contains a high-affinity, extracellular, and allosteric Zn 2+ (zinc ion) binding site which, upon zinc binding, inhibits dopamine reuptake, inhibits amphetamine-induced hDAT internalization, and amplifies amphetamine-induced dopamine efflux

Quantitative ultrastructural alterations in the lysosomal system

2.1% (consistent with weight loss rate) No Safety Signals: No increased risk of pancreatitis, thyroid tumors, or major CV events Historic Achievement: REDEFINE-1 demonstrated that CagriSema produces the highest mean weight loss (22.7%) ever reported for an obesity pharmacotherapy in a Phase 3 trial